Life Sciences Tools and Services

BNB Plus

Applied DNA Sciences released FY2025 Semi-Annual earnings on August 14 (EST), actual revenue USD 1.633 M, actual EPS USD 368.8427

Applied DNA Sciences released FY2025 9 Months Earnings on August 14 (EST), with actual revenue of USD 1.501 M and EPS of USD -397.3282

Applied DNA Sciences released FY2025 Q2 earnings on August 14 (EST), actual revenue USD 0 (forecast USD 1.185 M), actual EPS USD 0 (forecast USD -44.9999)

Applied DNA Sciences released FY2024 Q3 earnings on August 14 (EST), actual revenue USD 472.79K (forecast USD 1.079M), actual EPS USD 0 (forecast USD -371.2498)

Applied DNA Sciences released FY2024 9 Months Earnings on August 14, 2025 (EST) with actual revenue of USD 2.294 M and EPS of USD 0

Applied DNA Sciences released FY2025 Q3 earnings on August 14 (EST), actual revenue USD 304.39K (forecast USD 1.276M), actual EPS USD 20.2002 (forecast USD -37.4999)

Applied DNA Sciences released FY2024 Semi-Annual Earnings on May 15 (EST), with actual revenue of USD 1.821 M and EPS of USD 0

Applied DNA Sciences released FY2024 Q2 earnings on May 15 (EST), actual revenue USD 929.63 K (forecast USD 951 K), actual EPS USD 0

Applied DNA Sciences released FY2024 Q1 earnings on February 13 (EST), actual revenue USD 891.16 K (forecast USD 776 K), actual EPS USD 0

Applied DNA Sciences released FY2025 Q1 earnings on February 13 (EST), actual revenue USD 1.197 M (forecast USD 1.175 M), actual EPS USD -417.5284 (forecast USD -247.4998)

Applied DNA Sciences released FY2023 Q4 earnings on December 17, 2024 (EST), actual revenue USD 779.74K (forecast USD 1.681M), actual EPS USD 0

Applied DNA Sciences released FY2024 annual earnings on December 17 (EST), actual revenue USD 3.431 M (forecast USD 3.517 M), actual EPS USD 0 (forecast USD -3.27 K)

Applied DNA Sciences released FY2024 Q4 earnings on December 17 (EST), actual revenue USD 813.11 K (forecast USD 899 K), actual EPS USD -240.0074 (forecast USD -254.9998)

Applied DNA Sciences released FY2023 Annual Earnings on December 17 (EST), actual revenue USD 13.37 M (forecast USD 14.27 M), actual EPS USD 0

Mawson Infrastructure

Agape ATP

Petmed Express

AXIL Brands

HeartBeam

Black Titan

Diamond Hill Investment

Leverage Shares 2X Long GEMI Daily ETF

SMX Security Matters

Velo3D

Niagen Bioscience

ChromaDex

Agilent Tech

Waters

West Pharmaceutical

WuXi Biologics

Medpace

Repligen

Stevanato Group SpA

Cryoport

Style Score

Growth Score

Revenue YoY

Net Profit YoY

Value Score

P/B Ratio

Dividend Ratio

Size Score

Market Cap Score

Market Cap

Revenue Score

Revenue

Multi Score

Profit Score

Profit Margin

Gross Margin

Total Assets YoY

Net Assets YoY

Cash Score

Cash Flow Margin

OCF YoY

Operating Score

Turnover

Debt Score

Gearing Ratio

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap